Neurocrine Biosciences (NBIX) News Today $120.27 +1.49 (+1.25%) As of 05/15/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Lighthouse Investment Partners LLC Makes New $2.05 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lighthouse Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,000 shares of the company's stock, valued aMay 16 at 5:23 AM | marketbeat.comJacobs Levy Equity Management Inc. Sells 456,979 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Jacobs Levy Equity Management Inc. lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 87.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,189 shaMay 16 at 5:22 AM | marketbeat.comFocus Partners Wealth Purchases 4,420 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Focus Partners Wealth boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,078 shares of the company's stock after acquiring anMay 16 at 4:53 AM | marketbeat.comNeurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are BuyingMay 15 at 6:46 PM | insidermonkey.comNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITYâ„¢ (crinecerfont)May 15 at 4:19 PM | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Orbimed Advisors LLCOrbimed Advisors LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 210.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 938,120 shares of the company's stock aftMay 15 at 7:52 AM | marketbeat.comHudson Bay Capital Management LP Trims Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Hudson Bay Capital Management LP lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,342 shares of the company's stock after selling 9,658May 15 at 5:25 AM | marketbeat.comDeutsche Bank AG Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Deutsche Bank AG grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 461,782 shares of the company's stock after acquiring an additional 23,951 sharesMay 15 at 4:46 AM | marketbeat.comBank of America Corp DE Cuts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Bank of America Corp DE decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,034 shares of the companyMay 15 at 4:02 AM | marketbeat.comNeurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside PotentialMay 15 at 3:57 AM | finance.yahoo.comNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal HyperplasiaMay 14 at 4:05 PM | prnewswire.comIntegral Health Asset Management LLC Invests $21.84 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Integral Health Asset Management LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 160,000 shares of the company'May 14 at 6:17 AM | marketbeat.comNeurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside PotentialMay 13 at 4:42 PM | insidermonkey.comIron Triangle Partners LP Invests $43.43 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Iron Triangle Partners LP purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 318,195 shares of the company's stock, valued at appMay 13 at 8:22 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Ameriprise Financial Inc.Ameriprise Financial Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 413,479 shares of the company's stockMay 13 at 4:48 AM | marketbeat.comInvestors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings QualityMay 12, 2025 | finance.yahoo.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Driehaus Capital Management LLCDriehaus Capital Management LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,921 shares of the company's stock after acquiring an addMay 12, 2025 | marketbeat.comResearch Analysts Issue Forecasts for NBIX Q2 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report released on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings perMay 11, 2025 | marketbeat.comResearch Analysts Offer Predictions for NBIX Q2 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipatMay 11, 2025 | marketbeat.comBaird Financial Group Inc. Buys 24,657 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Baird Financial Group Inc. boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 82.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,717 shares of the company's stock after buying anMay 11, 2025 | marketbeat.comMercer Global Advisors Inc. ADV Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mercer Global Advisors Inc. ADV raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 52.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,112 shares of the company's stock after purchaMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Neurocrine Biosciences Lifted by AnalystMay 11, 2025 | americanbankingnews.comWedbush Has Negative Forecast for NBIX Q1 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Wedbush decreased their Q1 2026 EPS estimates for shares of Neurocrine Biosciences in a report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.10 per share for theMay 10, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for NBIX EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for Neurocrine Biosciences in a report released on Tuesday, May 6th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of $4.39 for theMay 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for NBIX FY2025 Earnings?Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Neurocrine Biosciences in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnMay 10, 2025 | marketbeat.comWhat is William Blair's Forecast for NBIX FY2025 Earnings?Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the companyMay 10, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for NBIX EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for Neurocrine Biosciences in a research note issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.May 10, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Sells 454,590 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Deerfield Management Company L.P. Series C lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 862,000 shares of the company's stock after selling 454,590 shMay 10, 2025 | marketbeat.comBNP Paribas Financial Markets Has $39.56 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)BNP Paribas Financial Markets cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 45.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,840 shares of the company'sMay 10, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Has $983,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Schonfeld Strategic Advisors LLC trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,200 shares of the company's stock aMay 10, 2025 | marketbeat.comWedbush Analysts Raise Earnings Estimates for NBIXMay 10, 2025 | americanbankingnews.comNeurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 9, 2025 | finance.yahoo.comWilliam H. Rastetter Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMay 9, 2025 | americanbankingnews.comBalyasny Asset Management L.P. Invests $26.58 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Balyasny Asset Management L.P. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 194,728 shares of the company's stMay 9, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysMay 9, 2025 | americanbankingnews.comWedbush Lowers Earnings Estimates for Neurocrine BiosciencesMay 9, 2025 | americanbankingnews.comFY2025 EPS Estimates for NBIX Lifted by Cantor FitzgeraldMay 9, 2025 | americanbankingnews.comHC Wainwright Analysts Boost Earnings Estimates for NBIXMay 9, 2025 | americanbankingnews.comNeurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at WedbushWedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Tuesday.May 8, 2025 | marketbeat.comPiper Sandler Reiterates "Overweight" Rating for Neurocrine Biosciences (NASDAQ:NBIX)Piper Sandler restated an "overweight" rating and set a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday.May 8, 2025 | marketbeat.comRoyal Bank of Canada Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $145.00Royal Bank of Canada increased their price target on Neurocrine Biosciences from $137.00 to $145.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $165.00Guggenheim boosted their target price on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research note on Tuesday.May 8, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given New $115.00 Price Target at BMO Capital MarketsBMO Capital Markets increased their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comUBS Group Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock PriceUBS Group lifted their target price on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the company a "buy" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up Following Analyst UpgradeNeurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up Following Analyst UpgradeMay 8, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00Canaccord Genuity Group increased their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comNeedham & Company LLC Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) StockNeedham & Company LLC raised their target price on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a report on Tuesday.May 8, 2025 | marketbeat.comNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient SubgroupsMay 8, 2025 | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director William H. Rastetter Sells 30,000 SharesMay 8, 2025 | insidertrades.com24,000 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Cercano Management LLCCercano Management LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,000 shares of the company's stock, valued at apprMay 8, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.880.79▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼4717▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Exelixis News Today Exact Sciences News Today Halozyme Therapeutics News Today Repligen News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 5/16/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredCan This System Really Predict Stocks to the Day?Imagine foreseeing a 30% stock jump — to the day — weeks before it happens. Introducing a new way to predict t...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredLenin was right all along… It’s not often you hear praise for a Bolshevik from a veteran investor… but Porter Stansberry says Lenin got o...Porter & Company | SponsoredPrepare now for May 31 eventMUST SEE: Elon Musk's latest project He's one of the most controversial men on the planet. But the Tesla fo...Stansberry Research | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts